PT - JOURNAL ARTICLE AU - Trager, Megan H AU - Wilkins, Kevin B AU - Koop, Mandy Miller AU - Bronte-Stewart, Helen TI - A Validated Measure of Rigidity in Parkinson’s Disease Using Alternating Finger Tapping on an Engineered Keyboard AID - 10.1101/2020.08.08.20170779 DP - 2020 Jan 01 TA - medRxiv PG - 2020.08.08.20170779 4099 - http://medrxiv.org/content/early/2020/08/11/2020.08.08.20170779.short 4100 - http://medrxiv.org/content/early/2020/08/11/2020.08.08.20170779.full AB - Introduction Reliable and accurate measures of rigidity have remained elusive in remote assessments of Parkinson’s disease (PD). This has severely limited the utility of telemedicine in the care and treatment of people with PD. It has also had a large negative impact on the scope of available outcomes, and on the costs, of multicenter clinical trials in PD. The goal of this study was to determine if quantitative measures from an engineered keyboard were sensitive and related to clinical measures of rigidity.Methods Sixteen participants with idiopathic PD, off antiparkinsonian medications, and eleven age-matched control participants performed a 30 second repetitive alternating finger tapping task on an engineered keyboard and were assessed with the Unified Parkinson’s Disease Rating Scale – motor (UPDRS-III).Results The speed of the key release was significantly slower in the PD compared to control cohorts (p <0.0001). In the PD cohort key release speed correlated with the lateralized upper extremity UPDRS III rigidity score (r = - 0.58, p < 0.0001), but not with the lateralized upper extremity tremor score (r = 0.14, p = 0.43).Conclusions This validated measure of rigidity complements our previous validation of temporal metrics of the repetitive alternating finger tapping task with the UPDRS III, bradykinesia and with the ability to quantify tremor, arrhythmicity and freezing episodes, and suggests that thirty seconds of alternating finger tapping on a portable engineered keyboard could transform the treatment of PD with telemedicine and the precision of multicenter clinical trials.Competing Interest StatementThe authors have declared no competing interest.Funding StatementParkinson's Foundation-Postdoctoral Fellowship (PF-FBS-2024), NIH-NINDS UH3NS107709, Robert and Ruth Halperin Foundation, John E Cahill Family Foundation. MHT was funded by the Parkinson's Disease Foundation Summer Student Fellowship (PDF-SFW-1330)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participants consented to participate in the study, which was approved by the Stanford Institutional Review BoardAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is provided in the manuscript text. Data sets can be requested from the authors.